Serge Jabbour

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes

Melanie J. Davies, Thomas R. Pieber, Marie‐Louise Hartoft‐Nielsen et al. · JAMA · 2017 · 446 citations · Full text

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

Juan P. Frías, Cristian Guja, Elise Hardy et al. · The Lancet Diabetes & Endocrinology · 2016 · 379 citations

Diabetes Management, Diabetes, Pharmacology +8

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Serge Jabbour, Elise Hardy, Jennifer Sugg et al. · Diabetes Care · 2013 · 279 citations

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Chantal Mathieu, Paresh Dandona, Pieter Gillard et al. · Diabetes Care · 2018 · 245 citations